At seven-years follow up, invasive disease-free survival was 80.8% with adjuvant T-DM1 and 67.1% with adjuvant trastuzumab alone. Overall survival was 89.1% with T-DM1 and 84.4% with trastuzumab ...

Zydus Lifesciences Limited reported a 30 per cent year-on-year increase in net profit to ₹1,023.5 crore for the quarter ended December 31, 2024, driven by robust performance in its US ...

The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with ...

(Image Credits: Pixabay) Zydus Lifesciences Ltd on Wednesday reported a profit of Rs 1023.80 crore during the third quarter of FY25, posting a growth of 29.66 per cent in comparison to Rs 789.60 ...

- Per. of shares (as a % of the total sh. of prom. and promoter group)----- - Per. of shares (as a % of the total Share Cap. of the company)----- Advisory Alert: It has come to our attention ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings. Higher sales of Mirabegron and new launches led ...

Magic Johnson is over the moon about the Lakers' surprise acquisition of former Dallas Mavericks superstar Luka Doncic over the weekend. On Sunday, the Showtime-era legend posted no fewer than ...

Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...

January 15, 2025--(BUSINESS WIRE)--Stoke Space, the rocket company building the world’s first 100% reusable medium-lift rocket, announced today that it has raised $260 million in new Series C ...

Zydus Lifesciences Limited (Formerly known ... Oxemia. It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla ...